Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Bought by Federated Hermes Inc.
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Bought by Federated Hermes Inc.
Federated Hermes Inc. boosted its position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) by 14.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,085,139 shares of the company's stock after buying an additional 134,206 shares during the period. Federated Hermes Inc. owned 1.90% of Zentalis Pharmaceuticals worth $30,492,000 as of its most recent SEC filing.
聯合愛馬仕公司在最近提交給美國證券交易委員會的信息中稱，該公司在第二季度將其在納斯達克(Sequoia PharmPharmticals，Inc.)股票的持倉量提高了14.1%。該公司持有1,085,139股該公司股票，在此期間又購買了134,206股。據聯合愛馬仕最近提交的美國證券交易委員會申請文件顯示，該公司持有Zentalis PharmPharmticals 1.90%的股份，價值30,492,000美元。
Several other institutional investors also recently added to or reduced their stakes in the company. Amundi acquired a new position in Zentalis Pharmaceuticals during the second quarter worth approximately $143,000. Legal & General Group Plc grew its stake in shares of Zentalis Pharmaceuticals by 38.1% in the 2nd quarter. Legal & General Group Plc now owns 35,491 shares of the company's stock valued at $998,000 after purchasing an additional 9,791 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Zentalis Pharmaceuticals by 49.9% in the 2nd quarter. Goldman Sachs Group Inc. now owns 397,570 shares of the company's stock valued at $11,171,000 after purchasing an additional 132,324 shares during the last quarter. Woodline Partners LP grew its stake in shares of Zentalis Pharmaceuticals by 344.9% in the 2nd quarter. Woodline Partners LP now owns 181,272 shares of the company's stock valued at $5,094,000 after purchasing an additional 140,524 shares during the last quarter. Finally, Thrivent Financial for Lutherans purchased a new position in shares of Zentalis Pharmaceuticals in the 2nd quarter valued at approximately $890,000.
其他幾家機構投資者最近也增持或減持了該公司的股份。Amundi在第二季度收購了Zentalis製藥公司的一個新頭寸，價值約為14.3萬美元。Legal&General Group Plc在第二季度增持了Zentalis PharmPharmticals的股份38.1%。Legal&General Group Plc現在擁有該公司35,491股股票，價值99.8萬美元，上個季度又購買了9,791股。高盛股份有限公司在第二季度增持了森特里斯製藥49.9%的股份。高盛股份有限公司在上個季度增持了132,324股後，目前持有397,570股該公司股票，價值11,171,000美元。Woodline Partners LP在第二季度增持了Zentalis製藥公司的股份，增幅為344.9%。Woodline Partners LP現在擁有181,272股該公司的股票，價值5094,000美元，在上個季度又購買了140,524股。最後，Thrient Financial for Lutherans在第二季度購買了新的Zentalis製藥公司股票，價值約89萬美元。
Zentalis Pharmaceuticals Stock Performance
Zentaris製藥類股表現
ZNTL opened at $19.38 on Friday. The business's fifty day moving average is $21.96 and its two-hundred day moving average is $24.96. The company has a market cap of $1.11 billion, a price-to-earnings ratio of -4.11 and a beta of 1.80. Zentalis Pharmaceuticals, Inc. has a one year low of $17.33 and a one year high of $85.95.
ZNTL上週五開盤報19.38美元。該業務的50日移動均線切入位為21.96美元，200日移動均線切入位為24.96美元。該公司市值為11.1億美元，市盈率為-4.11倍，貝塔係數為1.80。Zentalis PharmPharmticals，Inc.的一年低點為17.33美元，一年高位為85.95美元。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
Insiders Place Their Bets
內部人士下注
In other Zentalis Pharmaceuticals news, President Cam Gallagher sold 12,500 shares of the business's stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $22.77, for a total transaction of $284,625.00. Following the sale, the president now directly owns 372,011 shares in the company, valued at $8,470,690.47. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last ninety days, insiders have sold 50,000 shares of company stock worth $1,153,375. 19.90% of the stock is owned by corporate insiders.
另有消息稱，總裁·卡姆·加拉格爾在11月15日星期二的一次交易中出售了該公司12,500股票。該股以22.77美元的平均價格出售，總成交金額為284,625.00美元。出售後，總裁現在直接持有該公司372,011股，價值8,470,690.47美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可以通過美國證券交易委員會網站。在過去的90天裏，內部人士出售了5萬股公司股票，價值1,153,375美元。19.90%的股份由企業內部人士持有。
About Zentalis Pharmaceuticals
關於Zentaris製藥公司
(Get Rating)
(獲取評級)
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.
Zentalis製藥公司是一家臨牀階段的生物製藥公司，專注於發現和開發用於治療各種癌症的小分子療法。它的主要候選產品包括WEE1的抑制劑ZN-c3，這是一種蛋白質酪氨酸激酶，正處於治療晚期實體腫瘤的第二階段臨牀試驗；作為單一療法治療晚期實體腫瘤的第1/2階段臨牀試驗，以及正在進行的與鉑耐藥卵巢癌患者的聯合化療的1b階段臨牀試驗；以及腫瘤不可知的、可預測的生物標記物的第二階段單一治療試驗。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Zentalis Pharmaceuticals (ZNTL)
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
- Game-Changing News For Mullen Automotive
- Inflation and the Energy Crisis are Two Freight Trains on a Collision Course – Here's How to Prepare
- Is Enterprise Products Partners Fairly Valued?
- 免費獲取StockNews.com關於Zentalis製藥的研究報告(ZNTL)
- 拖拉機庫存能否突破杯柄收購點？
- 現在不是購買Lennar的時候，但時機即將到來
- 馬倫汽車公司改變遊戲規則的消息
- 通貨膨脹和能源危機是兩列相撞的貨運列車--以下是如何做好準備的
- 企業產品合作伙伴是否得到公平評價？
Want to see what other hedge funds are holding ZNTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating).
想看看其他對衝基金持有ZNTL嗎？訪問HoldingsChannel.com以獲取Zentalis製藥公司(納斯達克代碼：ZNTL-GET Rating)的最新13F備案文件和內幕交易信息。
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得Zentaris製藥日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Zentalis製藥公司和相關公司的最新新聞和分析師評級的每日簡要摘要。